MediPharm Labs (LABS) Competitors C$0.08 +0.01 (+15.38%) (As of 11/12/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlines LABS vs. TGOD, NINE, WMD, SUGR, MDP, VIR, ZOM, IN, META, and DBShould you be buying MediPharm Labs stock or one of its competitors? The main competitors of MediPharm Labs include Green Organic Dutchman (TGOD), Delta 9 Cannabis (NINE), WeedMD (WMD), SugarBud Craft Growers (SUGR), Medexus Pharmaceuticals (MDP), Viridium Pacific Group (VIR), Zomedica Pharmaceuticals Corp. (ZOM.V) (ZOM), InMed Pharmaceuticals (IN), Meta Growth (META), and Decibel Cannabis (DB). These companies are all part of the "drug manufacturers - specialty & generic" industry. MediPharm Labs vs. Green Organic Dutchman Delta 9 Cannabis WeedMD SugarBud Craft Growers Medexus Pharmaceuticals Viridium Pacific Group Zomedica Pharmaceuticals Corp. (ZOM.V) InMed Pharmaceuticals Meta Growth Decibel Cannabis MediPharm Labs (TSE:LABS) and Green Organic Dutchman (TSE:TGOD) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, community ranking, analyst recommendations, media sentiment, profitability, earnings, dividends and risk. Do insiders & institutionals hold more shares of LABS or TGOD? 0.7% of MediPharm Labs shares are owned by institutional investors. 4.5% of MediPharm Labs shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the MarketBeat Community believe in LABS or TGOD? Green Organic Dutchman received 154 more outperform votes than MediPharm Labs when rated by MarketBeat users. Likewise, 85.65% of users gave Green Organic Dutchman an outperform vote while only 65.79% of users gave MediPharm Labs an outperform vote. CompanyUnderperformOutperformMediPharm LabsOutperform Votes2565.79% Underperform Votes1334.21% Green Organic DutchmanOutperform Votes17985.65% Underperform Votes3014.35% Which has higher earnings & valuation, LABS or TGOD? MediPharm Labs has higher revenue and earnings than Green Organic Dutchman. MediPharm Labs is trading at a lower price-to-earnings ratio than Green Organic Dutchman, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMediPharm LabsC$37.76M0.82-C$13.31M-C$0.04-1.88Green Organic DutchmanC$31.37M0.00-C$137.58M-C$0.26N/A Does the media prefer LABS or TGOD? In the previous week, MediPharm Labs' average media sentiment score of 0.00 equaled Green Organic Dutchman'saverage media sentiment score. Company Overall Sentiment MediPharm Labs Neutral Green Organic Dutchman Neutral Is LABS or TGOD more profitable? Green Organic Dutchman has a net margin of 0.00% compared to MediPharm Labs' net margin of -35.25%. Green Organic Dutchman's return on equity of 0.00% beat MediPharm Labs' return on equity.Company Net Margins Return on Equity Return on Assets MediPharm Labs-35.25% -24.96% -7.17% Green Organic Dutchman N/A N/A N/A SummaryGreen Organic Dutchman beats MediPharm Labs on 6 of the 11 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get MediPharm Labs News Delivered to You Automatically Sign up to receive the latest news and ratings for LABS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip Chart LABS vs. The Competition Export to ExcelMetricMediPharm LabsDrug Manufacturers IndustryMedical SectorTSE ExchangeMarket CapC$30.83MC$1.14BC$5.23BC$5.81BDividend YieldN/A3.13%4.69%5.30%P/E Ratio-1.88104.23123.7926.14Price / Sales0.823,238.831,379.341,545.22Price / Cash1.3010.3539.4876.47Price / Book0.633.256.223.12Net Income-C$13.31MC$148.11MC$118.51MC$290.91M7 Day PerformanceN/A-2.01%1.01%-0.54%1 Month PerformanceN/A-3.83%6.71%0.48%1 Year PerformanceN/A95.41%42.96%42.85% MediPharm Labs Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LABSMediPharm LabsN/AC$0.08+15.4%N/A+7.1%C$30.83MC$37.76M-1.88130High Trading VolumeTGODGreen Organic DutchmanN/AC$0.17-2.9%N/AN/AC$89.95MC$31.37M-0.6541Gap UpHigh Trading VolumeNINEDelta 9 CannabisN/AC$1.03+3.0%N/A+0.0%C$89.36MC$12.87M19.07940Gap UpWMDWeedMDN/AC$0.28-1.8%N/A+0.0%C$67.82MC$27.53M-0.66628Gap UpSUGRSugarBud Craft GrowersN/AC$9.10+1.1%N/A+8,354.5%C$62.06MC$575.64M10.9644Gap UpMDPMedexus Pharmaceuticals2.7981 of 5 starsC$2.07-4.6%N/A+5.9%C$50.78MC$108.78M41.4098Analyst RevisionGap UpVIRViridium Pacific GroupN/AC$0.38+5.6%N/A+0.0%C$37.52MC$1.09M-2.97580Gap UpZOMZomedica Pharmaceuticals Corp. (ZOM.V)N/AC$0.29-6.6%N/A+0.0%C$36.73MN/A-2.6150Gap DownINInMed PharmaceuticalsN/AC$4.19-1.6%N/AN/AC$33.73MC$574,677.00-2.7712METAMeta GrowthN/AC$0.14flatN/A+0.0%C$33.14MC$60.96M-0.6686,500Gap DownDBDecibel Cannabis2.2365 of 5 starsC$0.08+7.1%N/A-40.7%C$30.68MC$105.60M-7.5083,000Gap Up Related Companies and Tools Related Companies Green Organic Dutchman Competitors Delta 9 Cannabis Competitors WeedMD Competitors SugarBud Craft Growers Competitors Medexus Pharmaceuticals Competitors Viridium Pacific Group Competitors Zomedica Pharmaceuticals Corp. (ZOM.V) Competitors InMed Pharmaceuticals Competitors Meta Growth Competitors Decibel Cannabis Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (TSE:LABS) was last updated on 11/13/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredYou just voted for a financial crisisI’d like to share with you my #1 high-conviction stock to buy before Inauguration Day… and details on the asse...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MediPharm Labs Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share MediPharm Labs With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.